gene therapy

Opus Genetics will present three abstracts at ASCRS 2026, including Phase 3 results for phentolamine ophthalmic solution treating presbyopia and mesopic vision issues.

Trogenix publishes Nature data showing 83% complete tumor elimination in aggressive brain cancer model. Phase I/II trial dosing planned for Q2 2026.

uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.

CRISPR Therapeutics advances promising pipeline candidates CTX310 and CTX320 targeting cardiovascular disease, though company remains unprofitable with minimal revenue.

Pomerantz Law Firm filed class action against $QURE after 49% stock decline following FDA concerns over gene therapy study data adequacy.

Global DNA read, write, edit market projected to surge from $21.4B in 2024 to $67.7B by 2030, driven by CRISPR advances and genomic diagnostics expansion.

Investors in $REGENXBIO face class action lawsuit alleging false statements about RGX-111 gene therapy development and clinical trial results spanning 2022-2026.

Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy. Lead plaintiff deadline April 14, 2026.

Securities lawsuit alleges REGENXBIO made misleading statements about RGX-111 gene therapy. Investors have until April 14, 2026 to file.

uniQure faces securities investigation after FDA publicly disputed the company's claims about regulatory guidance for gene therapy candidate AMT-130, with April 2026 deadline for investor class action.

Taysha Gene Therapies grants 300,000 RSUs and options to purchase 92,400 shares to four new employees under its 2023 Inducement Plan.

AAVantgarde Bio names Philip Lao as SVP of Business Development. Lao previously led Adverum's sale to Eli Lilly, bringing pharma expertise from Novartis, Pfizer, and Takeda.

AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.

Regenerative medicine market projected at $578B faces manufacturing bottleneck as Avaí Bio advances Master Cell Bank solution enabling scalable, off-the-shelf cell therapy production.

$QURE plummeted 49% after FDA feedback on AMT-130 gene therapy. Pomerantz Law Firm filed class action lawsuit; investor deadline April 13, 2026.

uniQure shares collapsed 49% after FDA signaled Phase I/II data insufficient for AMT-130 approval, prompting investors to file class action lawsuit.

Hagens Berman investigates $QURE over FDA allegations of misrepresented gene therapy data and manipulated study design. Stock tumbled 49% following November 3 FDA rebuttal.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Rosen Law Firm recruits lead plaintiffs for securities class action against REGENXBIO over alleged false statements regarding RGX-111 gene therapy trial data. Lead plaintiff deadline: April 14, 2026.